RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.99%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$707M
AUM Growth
+$707M
(+26%)
Cap. Flow
+$117M
Cap. Flow
% of AUM
16.59%
Top 10 Holdings %
Top 10 Hldgs %
27.95%
Holding
103
New
12
Increased
42
Reduced
34
Closed
6
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$18.6M |
| 2 |
UnitedHealth
UNH
|
$12.3M |
| 3 |
Cooper Companies
COO
|
$7.3M |
| 4 |
ESRX
Express Scripts Holding Company
ESRX
|
$7.03M |
| 5 |
Medtronic
MDT
|
$6.36M |
Top Sells
| 1 |
Amgen
AMGN
|
$4.61M |
| 2 |
OCR
OMNICARE INC
OCR
|
$3.85M |
| 3 |
Gilead Sciences
GILD
|
$3.4M |
| 4 |
Universal Health Services
UHS
|
$3.13M |
| 5 |
Ligand Pharmaceuticals
LGND
|
$3.01M |
Sector Composition
| 1 | Healthcare | 90.66% |
| 2 | Financials | 0.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Esperion Therapeutics
ESPR
$490M
| $9.16M | 1.1% |
112,000
-14,926
| -12% | -$1.22M |
|
27
Perrigo
PRGO
$3.21B
| $8.69M | 1.04% |
47,000
+27,000
| +135% | +$4.99M |
|
28
Becton Dickinson
BDX
$54.3B
| $8.5M | 1.02% |
61,500
+13,343
| +28% | +$1.84M |
|
29
Labcorp
LH
$22.8B
| $8.49M | 1.02% |
81,480
+36,084
| +79% | +$3.76M |
|
30
Acadia Pharmaceuticals
ACAD
$4.34B
| $8M | 0.96% |
191,000
+20,000
| +12% | +$838K |
|
31
Alnylam Pharmaceuticals
ALNY
$58.6B
| $7.36M | 0.88% |
61,400
+8,400
| +16% | +$1.01M |
|
32
DexCom
DXCM
$30.9B
| $7.36M | 0.88% |
368,000
+60,000
| +19% | +$1.2M |
|
|
33
Cooper Companies
COO
$13.3B
| $7.3M | 0.88% |
+164,000
| New | +$7.3M |
|
34
Bausch Health
BHC
$2.72B
| $7.16M | 0.86% |
32,248
-3,752
| -10% | -$834K |
|
35
Supernus Pharmaceuticals
SUPN
$2.52B
| $7.08M | 0.85% |
417,000
-33,800
| -7% | -$574K |
|
|
ESRX
36
DELISTED
Express Scripts Holding Company
ESRX
| $7.03M | 0.84% |
+79,000
| New | +$7.03M |
|
37
Community Health Systems
CYH
$392M
| $6.93M | 0.83% |
133,100
-9,680
| -7% | -$504K |
|
|
ABMD
38
DELISTED
Abiomed Inc
ABMD
| $6.84M | 0.82% |
104,000
+49,000
| +89% | +$3.22M |
|
39
Vertex Pharmaceuticals
VRTX
$102B
| $6.79M | 0.82% |
55,000
-3,000
| -5% | -$370K |
|
|
ITCI
40
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.58M | 0.79% |
206,000
+23,000
| +13% | +$735K |
|
|
AET
41
DELISTED
Aetna Inc
AET
| $6.5M | 0.78% |
51,000
+10,000
| +24% | +$1.27M |
|
42
HCA Healthcare
HCA
$95.4B
| $6.26M | 0.75% |
69,000
-5,000
| -7% | -$454K |
|
|
STJ
43
DELISTED
St Jude Medical
STJ
| $6.07M | 0.73% |
83,000
+34,200
| +70% | +$2.5M |
|
|
CYBX
44
DELISTED
CYBERONICS INC
CYBX
| $5.95M | 0.71% |
100,000
-8,000
| -7% | -$476K |
|
|
ICPT
45
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $5.79M | 0.7% |
24,000
+1,000
| +4% | +$241K |
|
|
CERN
46
DELISTED
Cerner Corp
CERN
| $5.73M | 0.69% |
83,000
+17,000
| +26% | +$1.17M |
|
47
Viatris
VTRS
$12.3B
| $5.63M | 0.68% |
+83,000
| New | +$5.63M |
|
48
McKesson
MCK
$85.9B
| $5.62M | 0.67% |
25,000
-13,000
| -34% | -$2.92M |
|
|
RVNC
49
DELISTED
Revance Therapeutics, Inc.
RVNC
| $5.5M | 0.66% |
172,000
-64,000
| -27% | -$2.05M |
|
50
Teva Pharmaceuticals
TEVA
$21.5B
| $5.44M | 0.65% |
92,000
+42,000
| +84% | +$2.48M |
|